Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc.

October 15, 2015

LAVAL, Quebec, Oct. 15, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) today announced that it has completed the previously announced acquisition of Synergetics USA, Inc. ("Synergetics"). Synergetics is a leading supplier of precision surgical devices. Synergetics' primary focus is on the surgical disciplines of ophthalmology and neurosurgery.

About Valeant Pharmaceuticals International, Inc.

Valeant is a multinational, specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products and medical devices primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at

www.valeant.com

Contact Information:

Laurie W. Little 949-461-6002 laurie.little@valeant.com

Elif McDonald 905-695-7607 elif.mcdonald@valeant.com

To view the original version on PR Newswire, visit:

http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-international-inc-completes-acquisition-of-synergetics-usa-inc-300160574.html

SOURCE Valeant Pharmaceuticals International, Inc.

Investor Inquiries

🦅 İi

<u>ir@bauschhealth.com</u> 877-281-6642 514-856-3855 (Canada)

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Media inquiries

<u>Corporate.communications@bauschhealth.com</u>

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u> <u>PERSONAL INFORMATION</u>

